Request for Research Proposals: Imbokodo HIV Vaccine Efficacy Trial (HVTN 705/VAC89220HPX2008)

Request for Research Proposals: Imbokodo HIV Vaccine Efficacy Trial (HVTN 705/VAC89220HPX2008)

The HIV Vaccine Trials Network (HVTN), the NIH/NIAID Division of AIDS (DAIDS), and Janssen Vaccines and Prevention are pleased to welcome scientific study proposals involving specimens and/or study data from the Imbokodo (HVTN 705/VAC89220HPX2008) HIV vaccine clinical trial.
HVTN News - February 07, 2023
Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review

Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review

HVTN researchers and ethicists say findings will help guide new approaches to HIV vaccine studies
News Releases - January 18, 2023

News on HVTN

Read MORE
A promising HIV vaccine candidate gets a little help New strategy stirs a robust response from T cells tracked by McElrath lab May 24, 2023
Year in Pictures: 2022 A look back at the year through compelling images December 12, 2022
Could a 100-year-old TB vaccine help scientists find a better one? Harmless vaccine BCG is made of living bacteria; in tests might serve as a proxy for deadly tuberculosis December 12, 2022
Dr. Larry Corey receives Alexander Fleming Award Virologist honored by peers for his lifetime achievements against infectious diseases October 21, 2022